Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
Vol 33
(15_suppl)
◽
pp. 501-501
◽
Keyword(s):
Keyword(s):
2018 ◽
Vol 30
(6)
◽
pp. 605-612
◽
2016 ◽